Alzheimer's Disease: Functional Therapeutics in Neurodegenerative Disease - References: An All-Creatures.org Vegan Health...
Mitochondrial iron loss from leukemia cells injured by macrophages. A possible mechanism for electron transport chain defects. ... Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL ... Anticancer Res 1998;18(1A):263-7. 43. Ibid. #3. 44. Steffen V, Santiago M, de la Cruz CP, Revilla E, Machado A, Cano J. Effect ...http://www.all-creatures.org/health/alzheimersdis-ref.html
miR-155 as a Biomarker in B-Cell Malignancies
H. Xue, L.-M. Hua, M. Guo, and J.-M. Luo, "SHIP1 is targeted by miR-155 in acute myeloid leukemia," Oncology Reports, vol. 32, ... The use of inhibiting anti-miR structures indicates promising potential as novel anticancer therapeutics. Reports from 53 ... Table 1: Cancer relevant target genes for miR-155 supported by experimental observations. ... K. Musilova and M. Mraz, "MicroRNAs in B-cell lymphomas: how a complex biology gets more complex," Leukemia, vol. 29, no. 5, pp ...https://www.hindawi.com/journals/bmri/2016/9513037/
Frontiers | Resistance to Cancer Treatment: The Role of Somatic Genetic Events and the Challenges for Targeted Therapies |...
Experimental models have pointed to a variety of explanations for resistance that have focused on cell survival and ... 2003). Androgen receptor mutations in androgen-in dependent prostate cancer: Cancer and Leukemia Group B Study 9663. J. Clin. ... The fundamental challenge in all anti-cancer therapeutics is resistance. This is true of all forms of therapy, in early disease ... This article provides a brief outline of the role of genomic mutations in therapeutic resistance to "targeted" anti-cancer ...https://www.frontiersin.org/articles/10.3389/fphar.2011.00059/full
Changes of Immunological Profiles in Patients with Chronic Myeloid Leukemia in the Course of Treatment
6Department of Experimental Virology, Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech ... which apparently plays a role in anticancer immunity, are also favorably influenced by IFNα [9, 10]. This might elucidate the ... J. L. Steegmann, G. Moreno, C. Aláez et al., "Chronic myeloid leukemia patients resistant to or intolerant of interferon α and ... M. W. N. Deininger, J. M. Goldman, and J. V. Melo, "The molecular biology of chronic myeloid leukemia," Blood, vol. 96, no. 10 ...https://www.hindawi.com/journals/jir/2010/137320/
Knockdown of COPS3 Inhibits Lung Cancer Tumor Growth in Nude Mice by Blocking Cell Cycle Progression
Expert Rev Anticancer Ther. 2006;6:515-30 24. Wu AB, Wu B, Guo JS, Luo WR, Wu D, Yang HL. et al. Elevated expression of CDK4 in ... Experimental cell research. 2015;337:61-7 17. Yin H, Chen N, Guo R, Wang H, Li W, Wang G. et al. Antitumor potential of a ... Friend leukemia virus integration 1 activates the Rho GTPase pathway and is associated with metastasis in breast cancer. ... Animals were purchased from the Experimental Animal Center of College of Basic Medical Sciences, Jilin University and were ...http://jcancer.org/v08p1129.htm
Is Gemtuzumab a Therapeutic Option in Older Patients with Acute Myeloid Leukemia? - The ASCO Post
The experimental arm extended event-free survival by just under 8 months. At 2 years, median event-free survival was 11.9 ... "Research has demonstrated that [gemtuzumab] has very potent anticancer properties, and with this study, we have identified a ... into the leukemia cells. The antibody is specifically targeted to the leukemia cells and theoretically spares toxicity to other ... Is Gemtuzumab a Therapeutic Option in Older Patients with Acute Myeloid Leukemia?. Drug was withdrawn from U.S. market in June ...http://www.ascopost.com/issues/february-15-2012/is-gemtuzumab-a-therapeutic-option-in-older-patients-with-acute-myeloid-leukemia/
Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
No chemotherapy, radiotherapy, immunotherapy, hormonal anticancer therapy, or. experimental medications (including approved ... Patients with SM, including mast cell leukemia (MCL).. - ECOG Performance Status (PS) 0-3. - Adequate renal function (indicated ...http://www.knowcancer.com/cancer-trials/NCT00493129/
Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS - Full Text View - ClinicalTrials...
Leukemia. Leukemia, Myeloid. Leukemia, Myeloid, Acute. Myelodysplastic Syndromes. Preleukemia. Disease. Pathologic Processes. ... Experimental: Treatment (combination chemotherapy) Patients receive bendamustine hydrochloride IV on days 1-5 and idarubicin IV ... Use of investigational agents within 30 days or any anticancer therapy within 2 weeks before study entry with the exception of ... Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With ...https://clinicaltrials.gov/ct2/show/NCT01141725
Boswellia sacra essential oil induces tumor cell-specific apoptosis and suppresses tumor aggressiveness in cultured human...
Anticancer Res. 2009, 29: 2987-2991.PubMedGoogle Scholar. *. Altmann A, Fischer L, Schubert-Zsilavecz M, Steinhilber D, Werz O ... AKBA is the most pronounced inhibitory effects among the 4 triterpene acids in suppressing human leukemia HL-60 cell growth as ... MS, KMF, CW, GY, and HKL conceived the idea, designed the experiments, and interpreted the experimental and clinical results. ... Anticancer Res. 2002, 22: 2853-2862.PubMedGoogle Scholar. *. Flavin DF: A lipoxygenase inhibitor in breast cancer brain ...https://bmccomplementalternmed.biomedcentral.com/articles/10.1186/1472-6882-11-129/
IJMS | Free Full-Text | Over-Expression of Deubiquitinating Enzyme USP14 in Lung Adenocarcinoma Promotes Proliferation...
Leukemia 2011, 25, 1516-1519. [Google Scholar]. *Liu, C.; Zhou, C.; Gao, F.; Cai, S.; Zhang, C.; Zhao, L.; Zhao, F.; Cao, F.; ... Comparisons between experimental groups and relevant controls were performed by Student's t test or ANOVA. Overall survival of ... the investigation and development of novel anticancer therapy based on inhibition of proteasome deubiquitinating activity or ... 3. Experimental Section. 3.1. Patients. Surgical specimens from 60 NSCLC patients (these samples consisted of 30 squamous ...http://mdpi.com/1422-0067/14/6/10749/htm
The Cisplatin-Induced Cellular Injury Response | SpringerLink
L1210 and leukemia and P388 leukemia). Southern Res Inst 1979; monograph #2.Google Scholar ... Breast Cancer: Experimental and Clinical Aspects. Oxford: Pergamon Press, 1980:199-212.Google Scholar ... Barry A, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and ... This process is experimental and the keywords may be updated as the learning algorithm improves. ...https://link.springer.com/chapter/10.1007/978-1-4899-0218-4_25
... the Experimental Therapeutics Award from the American Society of Pharmacology and Experimental Therapeutics, also in 2002, the ... acute myelogenous leukemia. C-8 or 90CE or VNP4090CE (in this study). 1,2-bis(methylsulfonyl)-1-(2-chloroethyl) hydrazine. C-7 ... 2010c) In vitro profiling and mass balance of the anti-cancer agent laromustine [14C]-VNP40101M by rat, dog, monkey and human ... Under the experimental conditions presented (Nassar et al., 2010b), and on the basis of the MS5 results, direct cleavage ...http://dmd.aspetjournals.org/content/44/8/1349
Anti-Inflammatory Effect of the Proteasome Inhibitor Bortezomib on Endotoxin-Induced Uveitis in Rats | IOVS | ARVO Journals
Adams J . The development of proteasome inhibitors as anticancer drugs. Cancer Cell . 2004;5:417-421. [CrossRef] [PubMed] ... Several experimental studies have noted that there is increased expression of activated NF-κB associated with EIU, and that the ... and reverse-transcribed to cDNA by using 80 U Moloney murine leukemia virus reverse transcriptase (MMLV-RT; Invitrogen-Gibco, ... Basler M Dajee M Moll C Groettrup M Kirk CJ . Prevention of experimental colitis by a selective inhibitor of the ...http://iovs.arvojournals.org/article.aspx?articleid=2127998
Open Sesame! 10 Amazing Health Benefits Of This Super-Seed
Multiple Sclerosis (MS): In the animal model of MS, also known as experimental autoimmune encephalomyelitis, sesame seed oil ... Sesamin's anticancer effects have been linked to the NF-kappaB signaling. ... 8] The Mechanism of Sesame Oil in Ameliorating Experimental Autoimmune Encephalomyelitis in C57BL/6 Mice. Phytother Res. 2011 ...http://www.greenmedinfo.com/blog/open-sesame-10-amazing-health-benefits-super-seed?utm_source=www.GreenMedInfo.com&utm_campaign=448a11468e-Greenmedinfo&utm_medium=email
Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström's Macroglobulinemia | Clinical Cancer...
The possible anticancer potential of resveratrol in WM, however, remains unknown. In this study, we evaluated the therapeutic ... Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2004;101:3118-23. ... Experimental Design: We studied resveratrol-induced inhibition of proliferation and induction of cytotoxicity in WM cell lines ... Resveratrol, an ingredient of wine, acts synergistically with ARA-C and Tiazofurin in HL-60 human promyelocytic leukemia cells ...http://clincancerres.aacrjournals.org/content/14/6/1849.long
Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL) - Full Text...
Experimental: Liposomal cytarabine Intrathecal liposomal cytarabine (25 - 50 mg) combined with intrathecal prednisolone sodium ... Known intolerance to NOPHO ALL 2008 anticancer agents. *Sexually active females will use safe contraceptives ... Leukemia. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Leukemia, Lymphoid. Neoplasms by Histologic Type. Neoplasms. ... Leukemia. Central nervous system. Neurotoxicity. Liposomal cytarabine. Children. Acute lymphoblastic leukemia. Childhood acute ...https://clinicaltrials.gov/ct2/show/NCT00991744
506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma - Tabular View -...
No anti-cancer treatment within the past three weeks. *ANC ,= 1,000/ul; may be included if in the judgment of the study ... Experimental: Treatment Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment repeats every 28 days for up to ... Recurrent Adult T-cell Leukemia/Lymphoma. *Recurrent Grade 1 Follicular Lymphoma. *Recurrent Grade 2 Follicular Lymphoma ...https://clinicaltrials.gov/ct2/show/record/NCT00005950?view=results
Head and neck cancer cell lines are resistant to mitochondrial-depolarization-induced apoptosis.
EXPERIMENTAL DESIGN: HNSCC cell lines JHU-011, -012 and -019, and a leukemia control cell line HL-60 were assayed for DeltaPsim ... 15824924 - Dinuclear platinum anticancer complexes with fluorescent n,n'-bis(aminoalkyl)-1,4-diami.... ...http://www.biomedsearch.com/nih/Head-neck-cancer-cell-lines/18483464.html
Frontiers | From antimicrobial to anticancer peptides. A review | Microbiology
... their use as anticancer peptides (ACPs) in cancer therapy either alone or in combination with other conventional drugs has been ... their use as anticancer peptides (ACPs) in cancer therapy either alone or in combination with other conventional drugs has been ... Moore, A. J., Devine, D. A., and Bibby, M. C. (1994). Preliminary experimental anticancer activity of cecropins. Pept. Res. 7, ... the designed polycationic peptides revealed a selective anticancer activity against cancer human acute T cell leukemia which ...https://www.frontiersin.org/articles/10.3389/fmicb.2013.00294/full
Antigen Shedding May Improve Efficiencies for Delivery of Antibody-Based Anticancer Agents in Solid Tumors | Cancer Research
A, experimental data of Onda and colleagues (24). The parameter values were chosen to give a best fit to this data set. B and C ... Generally, they work better on leukemias than against solid tumors, because of factors in solid tumors that are known to limit ... Many anticancer agents are composed of antibodies attached to cytotoxic drugs or protein toxins (1, 2). They bind to the ... There is strong experimental evidence that indicates that a RIT reservoir exists in the tumor tissue. Previously, we ...http://cancerres.aacrjournals.org/content/72/13/3143
Table of Contents | Clinical Cancer Research
The Role of Breast Cancer Resistance Protein in Acute Lymphoblastic Leukemia. Sabine L. A. Plasschaert, Dorina M. van der Kolk ... Experimental Therapeutics, Preclinical Pharmacology. *. Featured Articles Introduction of Midkine Gene into Human Bladder ... Enhancement of in Vivo Antitumor Activity of Classical Anticancer Agents by Combination with the New, Glutathione-Interacting ... Experimental Therapeutics, Preclinical Pharmacology. *. Regular Articles Angiosuppressive and Angiostimulatory Effects Exerted ...http://clincancerres.aacrjournals.org/content/9/14
Significance and prognostic value of increased serum direct bilirubin level for lymph node metastasis in Chinese rectal cancer...
Some experimental and clinical research has demonstrated that serum bilirubin has several protective effects including potent ... anti-inflammatory and anticancer activities[13-17]. In one study, the authors used their national, large health survey database ... including lymphoma and leukemia; (4) patients diagnosed with hereditary non-polyposis CRC and familial adenomatous polyposis; ( ... However, in recent years, some experimental and clinical research has demonstrated that serum bilirubin has several protective ...https://www.wjgnet.com/1007-9327/full/v22/i8/2576.htm
Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma - Full Text View -...
Leukemia, B-Cell. Leukemia, Lymphoid. Leukemia. Epstein-Barr Virus Infections. Herpesviridae Infections. DNA Virus Infections. ... Experimental: Treatment (tanespimycin) Patients will receive infusions of tanespimycin analogue twice a week in weeks 1 and 3. ... No other concurrent anticancer chemotherapy (e.g., cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP] or ... Leukemia, Lymphocytic, Chronic, B-Cell. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Lymphoma, Large B-Cell, Diffuse. ...https://clinicaltrials.gov/ct2/show/study/NCT00019708
Retinoid Signaling in Cancer and Its Promise for Therapy | OMICS International
Leukemia 9: 1467-1472. *Minucci S, Maccarana M, Cioce M, De Luca P, Gelmetti V, et al. (2000) Oligomerization of RAR and AML1 ... Anticancer Res 20: 1535-1543.. *Carrera S, Cuadrado-Castano S, Samuel J, Jones GD, Villar E, et al. (2013) Stra6, a retinoic ... Zhan et al. found that atRA downregulated CD80 and CD86 on dendritic cells in an experimental autoimmune encephalomyelitis ... Acute promyelocytic leukemia. To date, the most successful use of RA in cancer therapy has been in the treatment of APL. APL ...https://www.omicsonline.org/retinoid-signaling-in-cancer-and-its-promise-for-therapy-2157-2518-S7-006.php?aid=20426
Molecules | Free Full-Text | Kinetics of Glycoxidation of Bovine Serum Albumin by Methylglyoxal and Glyoxal and its Prevention...
Anticancer Res. 2013, 33, 13-20. [Google Scholar]. *Briski, K.P.; Patil, G.D. Induction of Fos immunoreactivity labeling in rat ... 4. Experimental. All basic reagents were from Sigma-Aldrich (Poznan, Poland) unless indicated otherwise. Glyoxal and ... with MGO concentrations up to 2.5 mM did not appear to have detectable deleterious effects on the viability of human leukemia ... 3-Bromopyruvate is a reactive derivative of pyruvate, inhibitor of glycolysis and a promising anticancer drug . This ...http://www.mdpi.com/1420-3049/19/4/4880/htm